Pet Medications in the U.S., 5th Edition
Attention: There is an updated edition available for this report.

Published Aug 25, 2017 |
192 Pages |
Pub ID: LA15184172

Special offer: now 20% off original full report price
Pet Medications in the U.S., 5th Edition
Pet Medications Market Shows Growth, Consolidation
The market for pet medications continues to show strong growth in the U.S. A raft of new products in the flea & tick category has redefined the landscape both in the veterinary market and in retail stores. Merial’s growth has been spurred on by its success in chewable flea & tick, Nexgard, which it sometimes pairs with its heartworm product, Heartgard, to boost sales in both categories. Elanco’s heartworm presence has increased as well, particularly due to aggressive marketing of Interceptor Plus to go along with its leading brand, Trifexis.
The pet medication industry has undergone consolidation, most notably with the closing of Boehringer Ingelheim’s acquisition of Merial, making BI the second-largest player globally. Other significant deals included PetIQ’s IPO and a large investment in Vets First Choice. The Vets First Choice investment points to the Internet's affect on pet meds distribution, ranging from mainstream channels such as Amazon, to Chewy.com as a pet product specialist, to pet drug-specific outlets such as 1-800-PetMeds.
Also factoring in are changes in the veterinary industry, including Mars’ acquisition of VCA. Overall pet medication sales growth continues to be affected negatively by cheaper options for consumers (e.g., competition among Frontline Plus and its various imitators), particularly as they are sold in brick-and-mortar and online channels where margins are lower. However, the strong pipeline of patented prescription drugs is helping to keep price erosion at bay.
Scope
Animal health products for production animals and horses are excluded from this market analysis, as are nutritional supplements for horses and companion animals, the latter of which
The report provides in-depth coverage of competitive trends, new product trends and marketing activity, and draws on insights from other reports in Packaged Facts’ extensive Pet Market Collection. Data provided include historical and projected market revenues, along with demographics and psychographics of pet med purchasers, based on data from sources including Simmons and Packaged Facts’ proprietary national pet owner surveys.
Report Methodology
Sales estimates are based on published and estimated sales of major market participants; market size estimates from other sources appearing in the trade press; figures obtained through consultation with market participants; the performance of relevant retail venues; consumer usage rates for pet medications; rates of company and product entries into the market; and sales data from syndicated resources.
Our consumer analysis draws primarily on two sources:
- Simmons National Consumer Surveys from Experian Marketing Services. On an ongoing basis, Experian Marketing Services conducts booklet-based surveys of a large and random sample of consumers (approximately 25,000 for each 12-month survey compilation) who in aggregate represent a statistically accurate cross-section of the U.S. population.
- Packaged Facts Pet Owner Surveys, including one conducted in June/July 2017. These surveys had a sample of 2,000 U.S. respondents age 18 or over who in aggregate are representative of the primary demographic measures of gender, age bracket, race/ethnicity, geographic region, household income bracket, and presence of children in the household of the U.S. Census Bureau.